Literature DB >> 9134974

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.

V H Sethy1, H Wu, J A Oostveen, E D Hall.   

Abstract

The neuroprotective effects of pramipexole, a dopamine agonist, were investigated in 3-acetylpyridine (3-AP)-treated Wistar rats. Bromocriptine was used as a reference compound to compare the results obtained with pramipexole. A significant reduction (P < 0.01) in cerebellar cGMP and ATP was observed 96 h after treatment with 3-AP (500 micromol/kg, i.p.). Both pramipexole and bromocriptine significantly attenuated 3-AP-induced reduction in cerebellar cGMP and ATP. Consistent with the neurochemical effect, both pramipexole and bromocriptine prevented 3-AP-induced loss of motor coordination. 3-Acetylpyridine produced a significant (P < 0.01) loss of neurons in the inferior olivary nucleus. Treatment with pramipexole and bromocriptine partially, but significantly (P < 0.01), prevented the loss of inferior olivary neurons. There was no reduction in the temperature of the animals, indicating that hypothermia was not responsible for neuroprotection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134974     DOI: 10.1016/s0006-8993(97)00075-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  The putative neuroprotective role of dopamine agonists in Parkinson's disease.

Authors:  F Grandas
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death.

Authors:  K Ishige; Q Chen; Y Sagara; D Schubert
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

Review 6.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 7.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Authors:  M Dooley; A Markham
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

Review 8.  Protection against Parkinson's disease progression: clinical experience.

Authors:  Peter A LeWitt; Danette C Taylor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 9.  G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.

Authors:  Zeinab Vahidinia; Mohammad Taghi Joghataei; Cordian Beyer; Mohammad Karimian; Abolfazl Azami Tameh
Journal:  Mol Neurobiol       Date:  2021-06-12       Impact factor: 5.590

10.  Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Authors:  Philippe Corcia; Paul H Gordon
Journal:  Ther Clin Risk Manag       Date:  2012-08-27       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.